Last updated: May 13, 2024
Sponsor: Institute of Liver and Biliary Sciences, India
Overall Status: Active - Recruiting
Phase
2/3
Condition
N/ATreatment
Inhalational isoflurane
Target control infusion propofol
Clinical Study ID
NCT06418893
IEC/2023/100/MA05
Ages 18-99 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:-Above 18 years of age who will undergo living donor liver transplant
Exclusion
Exclusion Criteria: Refusal to consent
Acute liver failure, Acute on chronic liver failure
Allergic to propofol or any component of propofol
Patients with pre existing cardiac dysfunction and cardiomyopathy
Patients with pre existing renal dysfunction/ deranged RFTs preoperatively
Study Design
Total Participants: 60
Treatment Group(s): 2
Primary Treatment: Inhalational isoflurane
Phase: 2/3
Study Start date:
August 01, 2023
Estimated Completion Date:
October 31, 2024
Connect with a study center
Institute of liver and biliary sciences
Delhi, 110070
IndiaActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.